| Literature DB >> 33500797 |
Babalola Ishamel Afolabi1, Bukunmi Michael Idowu2, Stephen Olaoluwa Onigbinde3.
Abstract
AIM OF STUDY: The main goal of this study was to compare the various degenerative changes in the Achilles tendon of type 2 diabetic patients to that of controls. The influence of diabetic peripheral neuropathy, duration of diabetes mellitus, age, and body mass index on the occurrence of degenerative changes was also evaluated.Entities:
Keywords: Achilles tendinopathy; Achilles tendon; diabetes mellitus; tendinopathy; tendon degeneration
Year: 2020 PMID: 33500797 PMCID: PMC7830069 DOI: 10.15557/JoU.2020.0051
Source DB: PubMed Journal: J Ultrason ISSN: 2084-8404
Fig. 1.Ultrasonography of a normal Achilles tendon (arrows) showing the transducer position and equivalent sonographic image in longitudinal/long-axis view (A, B) and transverse/short-axis view (C, D)
Fig. 2.B-mode ultrasound image of the Achilles tendon (longitudinal view) showing hypoechoic foci (arrows) within the tendon fibers (arrows)
Comparison of the degenerative changes in the AT of T2DM and controls
| Variables | Study group, | df | |||
|---|---|---|---|---|---|
| Diabetics ( | Controls ( | ||||
| Present | 4 (5.0) | 0 (0.0) | 0.120 | ||
| Absent | 76 (95.0) | 80 (100.0) | |||
| Present | 5 (6.3) | 2 (2.5) | 0.443 | ||
| Absent | 75 (93.8) | 78 (97.5) | |||
| Present | 43 (53.8) | 14 (17.5) | 22.919 | 1 | |
| Absent | 37 (46.3) | 66 (82.5) | |||
| Present | 41 (51.3) | 12 (15.0) | 23.728 | 1 | |
| Absent | 39 (48.8) | 68 (85.0) | |||
| Present | 16 (20.0) | 4 (5.0) | 8.229 | 1 | |
| Absent | 64 (80.0) | 76 (95.0) | |||
| Present | 15 (18.8) | 6 (7.5) | 4.440 | 1 | |
| Absent | 65 (81.2) | 74 (92.5) | |||
| Present | 44 (55.0) | 15 (18.8) | 22.581 | 1 | |
| Absent | 36 (45.0) | 65 (81.2) | |||
| Present | 42 (52.5) | 15 (18.8) | 19.867 | 1 | |
| Absent | 38 (47.5) | 65 (81.2) | |||
Fisher’s exact test * df – degree of freedom; AT – Achilles tendon; T2DM – type 2 diabetes mellitus
Fig. 3.B-mode ultrasound image of the Achilles tendon (longitudinal view) showing disorganization of the Achilles tendon fibers (arrows)
Fig. 4.B-mode ultrasound image of the Achilles tendon (transverse view) showing the presence of calcific focus (arrow) within the Achilles tendon fibers
Association between the degenerative changes and characteristics of T2DM subjects
| Variables | Degeneration | t | ||
|---|---|---|---|---|
| Present | Absent | |||
| AT disorganized fibers | ||||
| 63.8 ± 8.7 | 56.6 ± 11.0 | 3.132 | 0.003 | |
| 26.44 ± 4.36 | 25.14 ± 4.67 | 1.272 | 0.207 | |
| 8.7 ± 5.4 | 7.4 ± 2.4 | 1.409 | 0.163 | |
| 8.7 ± 2.8 | 8.2 ± 2.4 | 0.853 | 0.396 | |
| 67.0 (16.0–116.8) | 24.0 (6.0–61.8) | -2.294 | 0.022** | |
| 65.9 ± 7.2 | 59.7 ± 10.6 | 2.773 | 0.009 | |
| 25.86 ± 4.72 | 25.94 ± 4.49 | -0.068 | 0.946 | |
| 9.7 ± 7.3 | 7.8 ± 3.4 | 1.004 | 0.330 | |
| 9.5 ± 3.0 | 8.3 ± 2.5 | 1.757 | 0.083 | |
| 64.5 (28.5–103.0) | 37.5 (8.8–96.8) | -0.848 | 0.396** | |
| 65.5 ± 7.2 | 60.6 ± 10.5 | 1.134 | 0.260 | |
| 27.87 ± 5.52 | 25.77 ± 4.42 | 1.100 | 0.275 | |
| 7.9 ± 3.0 | 8.2 ± 4.6 | -0.144 | 0.886 | |
| 9.3 ± 3.8 | 8.5 ± 2.5 | 0.508 | 0.632 | |
| 65.0 (21.5–206.3) | 38.5 (7.5–96.3) | -1.042 | 0.298** | |
| 63.8 ± 8.7 | 56.5 ± 11.2 | 3.094 | 0.003 | |
| 26.41 ± 4.32 | 25.15 ± 4.74 | 1.219 | 0.227 | |
| 8.8 ± 5.4 | 7.3 ± 2.2 | 1.740 | 0.086 | |
| 8.8 ± 2.8 | 8.0 ± 2.2 | 1.395 | 0.167 | |
| 66.0 (17.0–116.5) | 23.0 (6.0–62.0) | -2.218 | 0.027** | |
* Any of AT calcification, disorganized fibers or hypoechoic foci; ** Mann-Whitney U test; T2DM - type 2 diabetes mellitus; AT - Achilles tendon
Comparison of disorganized fibers of AT with characteristics of diabetics
| Variables | Diabetics’ | df | ||||
|---|---|---|---|---|---|---|
| AT disorganized fibr | ||||||
| Present | Absent | Total | ||||
| 40–49 | 3 (20.0) | 12 (80.0) | 16 (100) | 12.315 | 3 | |
| 50–59 | 11 (68.8) | 5 (31.3) | 16 (100) | |||
| 60–69 | 20 (69.0) | 9 (31.0) | 29 (100) | |||
| 70–79 | 14 (70.0) | 6 (30.0) | 20 (100) | |||
| Male | 24 (80.0) | 6 (20.0) | 30 (100) | 8.000 | 1 | |
| Female | 24 (48.0) | 26 (52.0) | 50 (100) | |||
| Normal | 19 (51.4) | 18 (48.6) | 37 (100) | 2.233 | 2 | 0.327 |
| Overweight | 18 (69.2) | 8 (30.8) | 26 (100) | |||
| Obese | 11 (64.7) | 6 (35.3) | 17 (100) | |||
| <5 years | 20 (46.5) | 23 (53.5) | 43 (100) | 7.715 | 2 | |
| 5–10 years | 17 (70.8) | 7 (29.2) | 24 (100) | |||
| >10 years | 11 (84.6) | 2 (15.4) | 13 (100) | |||
| Present | 41 (71.9) | 16 (28.1) | 57 (100) | 11.757 | 1 | |
| Absent | 7 (30.4) | 16 (69.6) | 23 (100) | |||
| <5.6 (mmol/L) | 10 (62.5) | 6 (37.5) | 16 (100) | 0.059 | 2 | 0.971 |
| 5.6–6.9 (mmol/L) | 15 (60.0) | 10 (40.0) | 25 (100) | |||
| ≥7.0 (mmol/L) | 23 (59.0) | 16 (41.0) | 39 (100) | |||
| Poor (HbA1c ≥7.0%) | 32 (62.7) | 19 (37.3) | 51 (100) | 0.442 | 1 | 0.506 |
| Good (HbA1c <7.0%) | 16 (55.2) | 13 (44.8) | 29 (100) | |||
FBG – fasting blood glucose; HbA1c– glycated hemoglobin; BMI – body mass index; AT – Achilles tendon
Comparison of hypoechoic foci of AT with characteristics of T2DM subjects
| Variables | Diabetics’ | df | ||||
|---|---|---|---|---|---|---|
| AT hypoechoic foci | ||||||
| Present | Absent | Total | ||||
| 40–49 | 0 (0.0) | 15 (100.0) | 15 (100.0) | 0.060 | ||
| 50–59 | 2 (12.5) | 14 (87.5) | 16 (100.0) | |||
| 60–69 | 9 (31.0) | 20 (69.0) | 29 (100.0) | |||
| 70–79 | 5 (25.0) | 15 (75.0) | 20 (100.0) | |||
| Male | 9 (30.0) | 21 (70.0) | 30 (100.0) | 3.000 | 1 | 0.083 |
| Female | 7 (14.0) | 43 (86.0) | 50 (100.0) | |||
| Normal | 7 (18.9) | 30 (81.1) | 37 (100.0) | 1.526 | 2 | 0.466 |
| Overweight | 7 (26.9) | 19 (73.1) | 26 (100.0) | |||
| Obese | 2 (11.8) | 15 (88.2) | 17 (100.0) | |||
| <5 years | 6 (14.0) | 37 (86.0) | 43 (100.0) | 2.320 | 1 | 0.314 |
| 5–10 years | 7 (29.2) | 17 (70.8) | 24 (100.0) | |||
| >10 years | 3 (23.1) | 10 (76.9) | 13 (100.0) | |||
| Present | 15 (26.3) | 42 (73.7) | 57 (100.0) | |||
| Absent | 1 (4.3) | 22 (95.7) | 23 (100.0) | |||
| <5.6 (mmol/L) | 4 (25.0) | 12 (75.0) | 16 (100.0) | 0.506 | 2 | 0.776 |
| 5.6–6.9 (mmol/L) | 4 (16.0) | 21 (84.0) | 25 (100.0) | |||
| ≥7.0 (mmol/L) | 8 (20.5) | 31 (79.5) | 39 (100.0) | |||
| Poor (HbA1c ≥7.0%) | 11 (21.6) | 40 (78.4) | 51 (100.0) | 0.216 | 1 | 0.642 |
| Good (HbA1c <7.0%) | 5 (17.2) | 24 (82.8) | 29 (100.0) | |||
Fisher’s exact test; FBG – fasting blood glucose BMI – body mass index; T2DM – type 2 diabetes mellitus; AT – Achilles tendon
Achilles tendon calcifications compared by characteristics of T2DM subjects
| Variables | Diabetics’ | Total | ||
|---|---|---|---|---|
| AT calcifications | ||||
| Present | Absent | |||
| 40–49 | 0 (0.0) | 15 (100.0) | 15 (100.0) | 0.512 |
| 50–59 | 1 (6.3) | 15 (93.8) | 16 (100.0) | |
| 60–69 | 4 (13.8) | 25 (86.2) | 29 (100.0) | |
| 70–79 | 1 (5.0) | 19 (95.0) | 20 (100.0) | |
| Male | 3 (10.0) | 27 (90.0) | 30 (100.0) | 0.667 |
| Female | 3 (6.0) | 47 (94.0) | 50 (100.0) | |
| Normal | 3 (8.1) | 34 (91.9) | 37 (100.0) | 0.564 |
| Overweight | 1 (3.8) | 25 (96.2) | 26 (100.0) | |
| Obese | 2 (11.8) | 15 (88.2) | 17 (100.0) | |
| <5 years | 2 (4.7) | 41 (95.3) | 41 (100.0) | 0.295 |
| 5–10 years | 2 (8.3) | 22 (91.7) | 24 (100.0) | |
| >10 years | 2 (15.4) | 11 (84.6) | 13 (100.0) | |
| Present | 5 (8.8) | 52 (91.2) | 57 (100.0) | 0.667 |
| Absent | 1 (4.3) | 22 (95.7) | 23 (100.0) | |
| <5.6 (mmol/L) | 2 (12.5) | 14 (87.5) | 16 (100.0) | 0.203 |
| 5.6–6.9 (mmol/L) | 0 (0.0) | 25 (100.0) | 25 (100.0) | |
| ≥7.0 (mmol/L) | 4 (10.3) | 35 (89.7) | 39 (100.0) | |
| Poor (HbA1c ≥7.0%) | 3 (5.9) | 48 (94.1) | 51 (100.0) | 0.662 |
| Good (HbA1c <7.0%) | 3 (10.3) | 26 (89.7) | 29 (100.0) | |
Fisher’s exact test; AT – Achilles tendon; FBG – fasting blood glucose; T2DM – type 2 diabetes mellitus; PN – peripheral neuropathy; BMI – body mass index; HbA1c– glycated hemoglobin
Prevalence of various degenerative changes by characteristics of controls
| Variables | Present | Absent | Total | ||
|---|---|---|---|---|---|
| 40–49 | 0 (0.0) | 16 (100.0) | 16 (100.0) | ||
| 50–59 | 2 (13.3) | 13 (86.7) | 15 (100.0) | ||
| 60–69 | 7 (25.0) | 21 (75.0) | 28 (100.0) | ||
| 70–79 | 7 (33.3) | 14 (66.7) | 21 (100.0) | ||
| Male | 8 (23.5) | 26 (76.5) | 34 (100.0) | 0.460 | 0.497 |
| Female | 8 (17.4) | 38 (82.6) | 36 (100.0) | ||
| Normal | 7 (17.5) | 33 (82.5) | 40 (100.0) | 1.615 | 0.446 |
| Overweight | 8 (26.7) | 22 (73.3) | 30 (100.0) | ||
| Obese | 1 (10.0) | 9 (90.0) | 10 (100.0) | ||
| 40–49 | 0 (0.0) | 16 (100.0) | 16 (100.0) | ||
| 50–59 | 0 (0.0) | 15 (100.0) | 15 (100.0) | ||
| 60–69 | 2 (7.1) | 26 (92.9) | 28 (100.0) | ||
| 70–79 | 5 (23.8) | 16 (76.2) | 21 (100.0) | ||
| Male | 3 (8.8) | 31 (91.2) | 34 (100.0) | 1.000 | |
| Female | 4 (8.7) | 42 (91.3) | 46 (100.0) | ||
| Normal | 3 (7.5) | 37 (92.5) | 40 (100.0) | 0.327 | |
| Overweight | 2 (6.7) | 28 (93.3) | 30 (100.0) | ||
| Obese | 2 (20.0) | 8 (80.0) | 10 (100.0) | ||
| 40–49 | 0 (0.0) | 16 (100.0) | 16 (100.0) | 1.000 | |
| 50–59 | 0 (0.0) | 15 (100.0) | 15 (100.0) | ||
| 60–69 | 1 (3.6) | 27 (96.4) | 28 (100.0) | ||
| 70–79 | 1 (4.8) | 20 (95.2) | 21 (100.0) | ||
| Male | 0 (0.0) | 34 (100.0) | 34 (100.0) | 0.505 | |
| Female | 2 (4.3) | 44 (95.7) | 46 (100.0) | ||
| Normal | 1 (2.5) | 39 (97.5) | 40 (100.0) | 1.000 | |
| Overweight | 1 (3.3) | 29 (96.7) | 30 (100.0) | ||
| Obese | 0 (0.0) | 10 (100.0) | 10 (100.0) | ||
Fisher’s exact test;x2 - c hi-square; AT – Achilles ten don